This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: The Catholic University of Korea Industry-Academic Cooperation Foundation, University of Seoul Industry Cooperation Foundation. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Seung Ho Yang: Innovator in Cancer Survival Prediction
Introduction
Seung Ho Yang is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of medical technology, particularly in cancer research. His innovative work focuses on improving the survival prediction of patients suffering from non-small cell lung cancer with brain metastasis.
Latest Patents
Seung Ho Yang holds a patent for a method that predicts the survival of non-small cell lung cancer patients with brain metastasis. The patent, titled "Method for predicting survival of non-small cell lung cancer patients with brain metastasis," outlines a technique that compares the TMTrg of patients with a cutoff value to predict long-term survival. This invention is crucial for enhancing patient care and treatment planning.
Career Highlights
Seung Ho Yang is affiliated with the Catholic University of Korea Industry-Academic Cooperation Foundation. His role at this institution allows him to engage in cutting-edge research and collaborate with other experts in the field. His dedication to advancing medical technology has positioned him as a key figure in cancer research.
Collaborations
Seung Ho Yang has worked alongside notable colleagues, including Young Il Kim and Hyun Ho Kim. Their collaborative efforts contribute to the ongoing advancements in cancer treatment and patient care.
Conclusion
Seung Ho Yang's innovative approach to predicting cancer survival represents a significant advancement in medical technology. His work not only aids in understanding patient outcomes but also enhances the overall quality of care for those affected by non-small cell lung cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile